THE WOODLANDS, TX — August 4, 2026 — Leads & Copy — Autonomix Medical, Inc., a medical device company focused on advancing precision nerve-targeted treatments, announced the issuance of U.S. Patent No. 12,433,670. The patent, titled “Systems and Methods for Treating Cancer and/or Augmenting Organ Function,” enhances the company’s intellectual property for technologies designed to sense, map, and selectively target nerves associated with tumors, cancer-related pain, organ function, and other autonomic nervous system disorders.
The newly issued patent covers minimally invasive systems engineered to detect and map electrophysiological activity in nerves linked to tumors or metastatic cells. This information is then used to guide targeted treatment, employing catheter-based microsurgical tools capable of recording neural signals and delivering energy or therapeutic agents to selectively block or modulate identified nerves.
Technologies described within the patent are intended to sense and map electrophysiological activity associated with tumors or metastatic cells. The neural mapping data will identify and guide the treatment of targeted nerves. It will also enable the selective blocking or modulation of tumor-associated nerves to alleviate cancer-related pain. The systems can deliver therapeutic energy or agents via minimally invasive catheter-based approaches. Furthermore, the patent details the targeting of neural pathways that may influence tumors and their surrounding microenvironment, as well as the modulation of autonomic nervous system signaling related to organ function.
Potential applications detailed in the patent span a range of solid tumors, including pancreatic, prostate, breast, colorectal, liver, ovarian, and bone cancers.
“This patent represents another meaningful expansion of our intellectual property portfolio and further demonstrates the breadth of our proprietary technology platform,” said Brad Hauser, Chief Executive Officer of Autonomix Medical. “Our strategy is to build a comprehensive intellectual property portfolio spanning precision nerve sensing, physiologic assessment and targeted neuromodulation, with potential applications across cancer, organ function and other diseases involving the autonomic nervous system. This latest patent strengthens the foundation supporting that strategy while reinforcing the versatility and long-term potential of our platform.”
The patent complements Autonomix’s existing intellectual property portfolio, which includes prior patents covering autonomic nervous system assessment, neural sensing, treatment guidance, and transvascular neuromodulation technologies. These patents collectively support the company’s objective of developing differentiated technologies for precisely identifying and targeting disease-associated nerves across multiple therapeutic applications.
Autonomix continues to develop its proprietary technology platform, which is designed to detect and differentiate neural signals with significantly greater sensitivity than conventional technologies. This aims to support the creation of precision nerve-targeted therapies designed to enhance patient outcomes while minimizing unintended effects on surrounding tissue.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize the diagnosis and treatment of diseases involving the nervous system. The company’s platform system technology features a catheter-based microchip sensing array that may detect and differentiate neural signals with higher sensitivity than existing technologies. This could enable, for the first time, transvascular diagnosis and treatment of peripheral nervous system diseases throughout the body. The company is initially developing this technology for pain treatment, with early trials focused on pancreatic cancer, a condition known for its debilitating pain and lack of reliable solutions. The technology serves as a platform for addressing numerous potential indications, including cardiology, hypertension, and chronic pain management.
Source: Autonomix Medical, Inc.
